Highlights newsletter 1
This newsletter presents you the following key sessions:
1. Video-interview with Professor Richard Stone on the study results with the multi-kinase inhibitor midostaurin on
overall survival of AML patients
2. Ixazomib in combination with lenalidomide and dexamethasone significantly delays disease progression in patients
with relapsed/refractory multiple myeloma
3. Venetoclax monotherapy induces deep remissions in high-risk relapsed/refractory chronic lymphocytic leukemia
with a 17p deletion
4. Warfarin could be an acceptable alternative for long-term treatment of cancer-associated thrombosis
5. Real-time classification system based on cytogenetics and treatment response identifies leukemia patients with
an excellent outcome despite high-risk clinical features